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Background:  Phagocytosis of apoptotic cells by phagocytes is carried out by bridging the phosphatidylserine (PS)-expressing apoptotic cells 
and integrin _v`3-expressing phagocytes with lactadherin. The aim was to examine whether the microbubbles targeted to integrin _v`3 could be 
produced by conjugating PS-containing clinically available microbubbles (Sonazoid) with lactadherin.
Methods:  FACS analysis was performed to elucidate whether the lactadherin binds with Sonazoid bubbles or integrin _v`3-expressing cells 
(HUVECs). The attachment of Sonazoid bubbles to HUVECs was examined by using parallel plate flow chamber. The number of attached bubbles was 
compared before and after conjugating with lactadherin.
Results:  By increasing the dose of lactadherin, the number of lactadherin-bearing Sonazoid bubbles became larger. It was noteworthy that the size 
of Sonazoid bubbles did not change even after conjugating with lactadherin (2.90±0.04 vs. 2.81±0.02 μm). The binding between lactadherin and 
HUVECs was also confirmed by the FACS analysis. The parallel plate flow chamber study revealed that the number of attached Sonazoid bubbles to 
HUVECs was increased by conjugating with lactadherin (12.1±6.0 vs. 58.7±33.1 bubbles) (Figure).
Conclusion:  Because the integrin _v`3 is well known to play a key role in angiogenesis, the lactadherin-bearing Sonazoid bubbles has a 
feasibility to be a clinically translatable targeted ultrasound contrast agent for angiogenesis.
